| 2.76 0.44 (18.97%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.31 |
1-year : | 3.87 |
| Resists | First : | 2.83 |
Second : | 3.31 |
| Pivot price | 2.13 |
|||
| Supports | First : | 2.16 |
Second : | 1.75 |
| MAs | MA(5) : | 2.36 |
MA(20) : | 2.09 |
| MA(100) : | 2.19 |
MA(250) : | 1.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 72.4 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 3.34 | Low : | 0.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OKYO ] has closed above the upper band by 20.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.84 - 2.85 | 2.85 - 2.87 |
| Low: | 2.46 - 2.48 | 2.48 - 2.49 |
| Close: | 2.74 - 2.76 | 2.76 - 2.78 |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Tue, 06 Jan 2026
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com
Mon, 05 Jan 2026
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
Mon, 05 Jan 2026
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
Mon, 05 Jan 2026
OKYO Pharma names ophthalmology veteran Robert J Dempsey as CEO to drive next growth phase - MSN
Mon, 05 Jan 2026
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - GlobeNewswire
Mon, 05 Jan 2026
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 40.2 (%) |
| Held by Institutions | 6.8 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -169.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.13 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -23 |
| PEG Ratio | 0 |
| Price to Book value | -18.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -57.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|